Agent Capital

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs. The firm invests across all stages of development, from preclinical to commercial, partnering with scientists, entrepreneurs, and other investors to develop the next generation of healthcare innovations that positively impact patients' lives. Their key investment areas include rare diseases, oncology, neurology, and immunology.

The firm's strategy involves proactively guiding biotech companies through milestones and exits, with a deep understanding of biopharma's pipeline pressures. They make direct equity investments across all stages of development and types of financing rounds, aiming to move healthcare forward regardless of the stage or investment type.

Agent Capital's portfolio includes companies such as Dice Therapeutics, Freenome, Metagenomi, Pliant Therapeutics, ViTToria Biotherapeutics, Dragonfly Therapeutics, Carisma Therapeutics, Skyhawk Therapeutics, Flare Therapeutics, ImCheck Therapeutics, Orchard Therapeutics, Entrada Therapeutics, Zenas Biopharma, Star Therapeutics, Pyxis Oncology, Precision Biosciences, Palvella Therapeutics, Affini-T, AshiBio, Carbon Biosciences, Cerevance, Cyrus Biotechnology, Hinge Bio, Immunitas Therapeutics, Interius BioTherapeutics, Mediar Therapeutics, Orbital Therapeutics, Orbus Therapeutics, Palvella Therapeutics, Primrose Bio, Q32 Bio, Verge Genomics, and ViTToria Biotherapeutics.

Founded in 2016, Agent Capital is headquartered in Waltham, Massachusetts, United States. The firm has a team of 11-50 employees and manages assets under management (AUM) of approximately $63 million. Their investment horizon typically spans 3-5 years, with an investment ticket size ranging from $500,000 to $15 million. The firm primarily invests in seed, Series A, Series B, and Series C stages, with exit strategies including sale to strategic investors and initial public offerings (IPOs).